Research Analysts Set Expectations for TERN Q1 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Terns Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of ($0.30) for the quarter. HC Wainwright has a “Neutral” rating and a $7.50 price target on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.28) per share.

Other analysts have also issued research reports about the stock. BMO Capital Markets restated an “outperform” rating and set a $26.00 price target (up previously from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. Oppenheimer initiated coverage on shares of Terns Pharmaceuticals in a research report on Thursday, October 31st. They set an “outperform” rating and a $82.00 price target on the stock. Finally, JMP Securities lifted their target price on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the company a “market outperform” rating in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Terns Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $27.25.

Terns Pharmaceuticals Stock Performance

TERN stock opened at $6.55 on Thursday. The firm has a market cap of $460.73 million, a PE ratio of -5.75 and a beta of -0.32. The firm’s fifty day moving average is $8.08 and its 200 day moving average is $7.46. Terns Pharmaceuticals has a one year low of $3.51 and a one year high of $11.40.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. raised its stake in shares of Terns Pharmaceuticals by 21.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,690,376 shares of the company’s stock valued at $18,321,000 after acquiring an additional 469,176 shares during the period. Vanguard Group Inc. increased its stake in Terns Pharmaceuticals by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 2,199,006 shares of the company’s stock worth $14,425,000 after buying an additional 11,535 shares during the period. Janus Henderson Group PLC increased its stake in Terns Pharmaceuticals by 40.6% during the 1st quarter. Janus Henderson Group PLC now owns 2,003,263 shares of the company’s stock worth $13,131,000 after buying an additional 578,500 shares during the period. Bellevue Group AG purchased a new stake in Terns Pharmaceuticals during the 3rd quarter worth approximately $8,691,000. Finally, Russell Investments Group Ltd. increased its stake in Terns Pharmaceuticals by 127.9% during the 1st quarter. Russell Investments Group Ltd. now owns 632,965 shares of the company’s stock worth $4,152,000 after buying an additional 355,224 shares during the period. 98.26% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Hongbo Lu bought 476,190 shares of Terns Pharmaceuticals stock in a transaction on Thursday, September 12th. The shares were bought at an average cost of $10.50 per share, with a total value of $4,999,995.00. Following the completion of the purchase, the director now directly owns 476,190 shares of the company’s stock, valued at approximately $4,999,995. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jill M. Quigley sold 17,235 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $10.00, for a total transaction of $172,350.00. Following the completion of the sale, the director now directly owns 15,000 shares in the company, valued at $150,000. This trade represents a 53.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.10% of the stock is currently owned by company insiders.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.